MAGEA4

Melanoma-associated antigen 4 is a protein that in humans is encoded by the MAGEA4 gene.^[3][4]

MAGEA4
Available structures PDB Human UniProt search: PDBe RCSB List of PDB id codes 1I4F, 2WA0
Identifiers
Aliases	MAGEA4, CT1.4, MAGE-41, MAGE-X2, MAGE4, MAGE4A, MAGE4B, MAGE family member A4
External IDs	OMIM: 300175; HomoloGene: 134073; GeneCards: MAGEA4; OMA:MAGEA4 - orthologs
Gene location (Human) Chr. X chromosome (human)[1] Band Xq28 Start 151,912,509 bp[1] End 151,925,170 bp[1]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in testicle right testis left testis gonad placenta renal cortex lymph node human musculoskeletal system endometrium muscular system n/a More reference expression data BioGPS More reference expression data
Gene ontology Molecular function protein binding molecular function Cellular component cellular component Biological process biological process Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 4103 n/a Ensembl ENSG00000147381 n/a UniProt P43358 n/a RefSeq (mRNA) NM_001011548 NM_001011549 NM_001011550 NM_002362 n/a RefSeq (protein) NP_001011548 NP_001011549 NP_001011550 NP_002353 n/a Location (UCSC) Chr X: 151.91 – 151.93 Mb n/a PubMed search [2] n/a
Wikidata
View/Edit Human

This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls.

Clinical importance

The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. At least four variants encoding the same protein have been found for this gene.^[4]

In salivary gland carcinomas, MAGE4 expression correlates to lower-grade histology, lower likelihood of metastases and more favourable survival.^[5]

While MAGEA4 is expressed by many tumours,^[6] it is almost universally expressed by synovial sarcomas.^[7] A targeted treatment to use genetically modified autologous T cells is (as of June 2021^[update]) undergoing clinical trials.^[8]